BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

Japan's Veritas In Silico partners with SpiroChem for discovery of next generation RNA drugs

28 January 2026 | News

Deepen understanding of structure–activity relationships for RNA recognition and define design criteria that can inform future programmes

Swiss firm SpiroChem AG and Japan-based Veritas In Silico Inc. have announced the signing of a Memorandum of Understanding (MoU) to collaborate on the discovery and experimental validation of RNA modulating chemical matter. The collaboration brings together VIS's advanced artificial intelligence (AI) driven RNA design platform with SpiroChem's world class macrocycle, peptide and peptoid chemistry capabilities.

Under the MoU, the parties intend to jointly explore novel macrocycles, peptides, peptoids and beyond Rule of 5 *1 scaffolds that interact with RNA motifs of interest. The teams aim to generate high value experimental data, deepen understanding of structure–activity relationships for RNA recognition, and define design criteria that can inform future programs.

"This collaboration pairs VIS's leading RNA structure analytics and design with SpiroChem's depth in macrocycles and peptide chemistry," said Thomas Fessard, CEO and Co founder of SpiroChem. "Together we aim to expand the frontier of RNA binding chemical space and deliver high quality data that benefits partners across the RNA modulator field."

"Combining our AI powered platform with SpiroChem's libraries and medicinal chemistry expertise creates a powerful engine to evaluate and mature novel RNA binding scaffolds," said Shingo Nakamura, CEO and Founder of Veritas In Silico. "We look forward to the scientific insights and collaboration opportunities this work can enable."

Based on outcomes, the parties may explore future partnering, licensing or co development opportunities with biotech and pharmaceutical companies.